Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Mar 31, 2025 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 9.52%20.76B | -0.44%18.95B | -6.81%4.09B | 3.23%5.37B | -0.39%4.86B | 1.44%4.64B | -0.51%19.04B | -1.13%4.39B | 1.56%5.2B | 0.29%4.87B |
| Cost of revenue | 6.80%17.1B | -4.30%16.01B | -12.53%3.41B | -1.96%4.5B | -3.02%4.15B | -0.33%3.96B | 6.05%16.73B | 3.26%3.9B | 9.29%4.59B | 6.55%4.28B |
| Gross profit | 24.32%3.66B | 27.60%2.94B | 38.34%682M | 42.13%867M | 18.43%707M | 13.25%684M | -31.37%2.3B | -25.98%493M | -33.70%610M | -29.43%597M |
| Operating expense | 0.12%3.42B | -2.51%3.42B | -4.08%799M | -4.86%841M | 1.59%896M | -2.76%880M | -5.12%3.5B | -13.68%833M | -5.96%884M | -2.97%882M |
| Staff costs | 1.42%1.14B | -9.29%1.12B | -10.32%278M | -10.82%272M | -7.05%290M | -9.00%283M | -4.84%1.24B | -5.20%310M | -5.28%305M | -6.02%312M |
| Selling and administrative expenses | -1.46%540M | -11.47%548M | -11.35%125M | -4.55%147M | -18.13%140M | -11.11%136M | -2.06%619M | -20.34%141M | -2.53%154M | 12.50%171M |
| -Selling and marketing expense | 29.55%57M | -32.31%44M | -33.33%8M | -41.18%10M | -27.27%16M | -28.57%10M | 4.84%65M | 9.09%12M | -10.53%17M | 10.00%22M |
| -General and administrative expense | -4.17%483M | -9.03%504M | -9.30%117M | 0.00%137M | -16.78%124M | -9.35%126M | -2.81%554M | -22.29%129M | -1.44%137M | 12.88%149M |
| Research and development costs | -15.97%121M | -11.66%144M | -11.43%31M | -9.76%37M | -2.70%36M | -20.00%40M | -20.87%163M | -31.37%35M | -29.31%41M | -19.57%37M |
| Depreciation and amortization | -3.15%123M | -7.30%127M | -5.88%32M | -11.43%31M | 0.00%32M | -11.11%32M | -12.74%137M | -22.73%34M | -14.63%35M | -11.11%32M |
| -Depreciation | -3.15%123M | -7.30%127M | -5.88%32M | -11.43%31M | 0.00%32M | -11.11%32M | -12.74%137M | -22.73%34M | -14.63%35M | -11.11%32M |
| Other operating expenses | 1.56%1.5B | 9.43%1.47B | 6.39%333M | 1.43%354M | 20.61%398M | 9.58%389M | -3.58%1.35B | -14.48%313M | -3.32%349M | -3.79%330M |
| Operating profit | 149.37%235M | 60.33%-476M | 65.59%-117M | 109.49%26M | 33.68%-189M | 34.88%-196M | -257.14%-1.2B | -13.71%-340M | -1,270.00%-274M | -352.38%-285M |
| Net non-operating interest income (expenses) | -31.82%-58M | -144.44%-44M | -9.09%-12M | -333.33%-13M | -233.33%-10M | -800.00%-9M | -157.14%-18M | -450.00%-11M | -50.00%-3M | -50.00%-3M |
| Non-operating interest income | 200.00%3M | --1M | --1M | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Non-operating interest expense | 35.56%61M | 150.00%45M | 18.18%13M | 333.33%13M | 233.33%10M | 800.00%9M | 157.14%18M | 450.00%11M | 50.00%3M | 50.00%3M |
| Net investment income | -14.29%18M | -8.70%21M | -50.00%1M | 0.00%7M | 100.00%2M | -15.38%11M | 21.05%23M | 100.00%2M | 16.67%7M | 0.00%1M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 71M | 0 | 0 | 0 | 6,700.00%68M | 6M | ||||
| Income from associates and other participating interests | 17.61%354M | 72.99%301M | 105.26%39M | 38.03%98M | 131.43%81M | 69.39%83M | 70.59%174M | 216.67%19M | 787.50%71M | 9.38%35M |
| Special income (charges) | -356.80%-321M | 121.33%125M | 180.59%137M | 97.27%-3M | 97.65%-6M | 94.12%-3M | 22.49%-586M | 77.45%-170M | -10,900.00%-110M | -25,400.00%-255M |
| Less:Other special charges | 328.47%313M | -123.38%-137M | -187.65%-149M | -97.27%3M | -97.65%6M | -94.12%3M | 57.53%586M | -54.05%170M | 10,900.00%110M | --255M |
| Less:Write off | -33.33%8M | --12M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| Other non-operating income (expenses) | 71.65%-74M | -113.93%-261M | -131M | 102.11%3M | -713.33%-122M | 0 | -273.68%-142M | 100.00%12M | ||
| Income before tax | 166.27%222M | 79.88%-335M | 83.43%-82M | 130.77%120M | 48.08%-257M | 59.30%-116M | -66.67%-1.67B | 52.63%-495M | -712.50%-390M | -1,880.00%-495M |
| Income tax | 64.00%164M | 13.64%100M | -41.67%7M | 71.43%36M | 20.83%29M | -9.68%28M | -88.48%88M | -98.13%12M | -22.22%21M | -55.56%24M |
| Net income | 113.30%58M | 75.14%-436M | 82.28%-90M | 120.73%85M | 45.00%-286M | 54.11%-145M | 0.51%-1.75B | 69.87%-508M | -446.67%-410M | -566.67%-520M |
| Net income continuous operations | 113.33%58M | 75.19%-435M | 82.45%-89M | 120.44%84M | 44.89%-286M | 54.43%-144M | 0.57%-1.75B | 69.93%-507M | -448.00%-411M | -556.96%-519M |
| Noncontrolling interests | 93.44%118M | 17.31%61M | -44.44%5M | 35.00%27M | 70.00%17M | -7.69%12M | -16.13%52M | 50.00%9M | 17.65%20M | -52.38%10M |
| Net income attributable to the company | 88.13%-59M | 72.48%-497M | 81.78%-94M | 113.26%57M | 43.13%-302M | 51.98%-158M | 1.04%-1.81B | 69.49%-516M | -362.37%-430M | -436.36%-531M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 88.13%-59M | 72.48%-497M | 81.78%-94M | 113.26%57M | 43.13%-302M | 51.98%-158M | 1.04%-1.81B | 69.49%-516M | -362.37%-430M | -436.36%-531M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 88.04%-1.92 | 72.48%-16.05 | 81.83%-3.03 | 113.40%1.86 | 42.94%-9.78 | 52.02%-5.1 | 1.05%-58.33 | 69.46%-16.68 | -365.77%-13.88 | -430.65%-17.14 |
| Diluted earnings per share | 88.04%-1.92 | 72.48%-16.05 | 81.81%-3.0345 | 113.26%1.8401 | 42.95%-9.78 | 52.02%-5.1 | 1.05%-58.33 | 69.46%-16.68 | -362.37%-13.8812 | -430.70%-17.1417 |
| Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |